Akshay Sood to Prostate-Specific Antigen
This is a "connection" page, showing publications Akshay Sood has written about Prostate-Specific Antigen.
Connection Strength
5.835
-
Sood A, Keeley J, Palma-Zamora I, Chien M, Corsi N, Jeong W, Rogers CG, Trinh QD, Peabody JO, Menon M, Abdollah F. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. Ann Surg Oncol. 2022 Oct; 29(11):7206-7215.
Score: 0.689
-
Sood A, Keeley J, Palma-Zamora I, Arora S, Dalela D, Olson P, Hanna R, Cotter D, Jeong W, Elshaikh M, Rogers CG, Peabody JO, Menon M, Abdollah F. Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data. Urol Oncol. 2020 06; 38(6):599.e1-599.e8.
Score: 0.594
-
Bertini A, Stephens A, Finocchiaro A, Vigan? S, Perri A, Lughezzani G, Buffi N, Sorce G, Ficarra V, Briganti A, Salonia A, Montorsi F, Sood A, Menon M, Rogers C, Abdollah F. Mortality and Additional Treatment Rates in Pathologically High-Risk Prostate Cancer With Prostate-Specific Antigen Persistence at Robot-Assisted Radical Prostatectomy: Long-Term Report From Single Tertiary Referral Center. Prostate. 2025 Dec; 85(16):1457-1467.
Score: 0.215
-
Bertini A, Cirulli GO, Stephens A, Finocchiaro A, Vigan? S, Lughezzani G, Buffi N, Di Trapani E, Ficarra V, Salonia A, Briganti A, Montorsi F, Sood A, Rogers C, Abdollah F. Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency. BJU Int. 2025 Nov; 136(5):818-825.
Score: 0.215
-
Cirulli GO, Stephens A, Chiarelli G, Finati M, Bertini A, Chase M, Tinsley S, Arora S, Sood A, Lughezzani G, Buffi N, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort. Prostate. 2025 May; 85(6):531-540.
Score: 0.208
-
Chiarelli G, Davis M, Stephens A, Finati M, Cirulli GO, Morrison C, Sood A, Carrieri G, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate-Specific Antigen. Prostate. 2025 Mar; 85(4):354-363.
Score: 0.206
-
Stephens A, Morrison C, Lutchka J, Richard C, Hares K, Tinsley S, Sood A, Shannon B, Rogers C, Shill J, Shakir N, Abdollah F. Prostate Cancer Screening and Diagnoses in the Transfeminine Population. Urology. 2025 03; 197:80-87.
Score: 0.205
-
Finati M, Stephens A, Cirulli GO, Chiarelli G, Tinsley S, Morrison C, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Rogers C, Carrieri G, Abdollah F. Association of race and area of deprivation index with prostate cancer incidence and lethality: results from a contemporary North American cohort. JNCI Cancer Spectr. 2024 Nov 01; 8(6).
Score: 0.204
-
Cirulli GO, Davis M, Stephens A, Chiarelli G, Finati M, Chase M, Tinsley S, Arora S, Sood A, Lughezzani G, Buffi N, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality. Cancer. 2025 Jan 01; 131(1):e35563.
Score: 0.203
-
Cirulli GO, Davis M, Stephens A, Chiarelli G, Finati M, Corsi N, Williams E, Affas R, Sood A, Buffi N, Lughezzani G, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis. J Urol. 2024 Oct; 212(4):560-570.
Score: 0.201
-
Finati M, Davis M, Stephens A, Chiarelli G, Cirulli GO, Morrison C, Affas R, Sood A, Buffi N, Lughezzani G, Briganti A, Montorsi F, Carrieri G, Rogers C, Vickers AJ, Abdollah F. The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort. Eur Urol Oncol. 2024 Dec; 7(6):1535-1542.
Score: 0.200
-
Chiarelli G, Davis M, Stephens A, Cirulli GO, Finati M, Corsi NJ, Sood A, Tinsley S, Carrieri G, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. Comparison of patient background between a real-world North American cohort and the G?teborg-2 trial. Int J Urol. 2024 May; 31(5):562-567.
Score: 0.194
-
Dalela D, Corsi NJ, Bronkema C, Sood A, Arora S, Majdalany SE, Butaney M, Jamil M, Li P, Palma-Zamora I, Rakic N, Kovacevic N, Jeong W, Menon M, Rogers CG, Schonberg MA, Abdollah F. Prostate Specific Antigen Screening on a Nationwide Level: Featuring the Contribution of Race and Life Expectancy in Decision Making. Clin Genitourin Cancer. 2024 04; 22(2):269-280.e2.
Score: 0.191
-
Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. Eur Urol Oncol. 2024 Feb; 7(1):27-43.
Score: 0.186
-
Dalela D, Malchow T, Butaney M, Majdalany S, Corsi NJ, Rakic I, Sood A, Rogers C, Abdollah F. Temporal and Racial Trends in Prostate-specific Antigen Screening for U.S. Men With a Family History of Prostate Cancer. Urol Pract. 2023 09; 10(5):484-492.
Score: 0.186
-
Sood A, Grauer R, Diaz-Insua M, Tewari AK, Hemal AK, Shrivastava A, Peabody JO, Jeong W, Abdollah F, Rudzinski JK, Andrews JR, Gorin MA, Bhandari M, Menon M. 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer. Prostate Cancer Prostatic Dis. 2023 12; 26(4):778-786.
Score: 0.184
-
Sood A, Zhang LT, Keeley J, Butaney M, Stricker M, Andrews JR, Grauer R, Peabody JO, Rogers CG, Menon M, Abdollah F. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer Prostatic Dis. 2024 Mar; 27(1):58-64.
Score: 0.174
-
Sood A, Jeong W, Palma-Zamora I, Abdollah F, Butaney M, Corsi N, Wurst H, Arora S, Kachroo N, Hassan O, Gupta N, Gorin MA, Menon M. Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study). Eur Urol. 2022 Apr; 81(4):396-406.
Score: 0.167
-
Dalela D, Sood A, Keeley J, Rogers C, Menon M, Abdollah F. Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World" Setting: A Nationwide Survey Analysis. Urology. 2021 02; 148:1-3.
Score: 0.155
-
Vetterlein MW, Dalela D, Sammon JD, Karabon P, Sood A, Jindal T, Meyer CP, L?ppenberg B, Sun M, Trinh QD, Menon M, Abdollah F. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. Urology. 2018 Feb; 112:56-65.
Score: 0.125
-
Jindal T, Kachroo N, Sammon J, Dalela D, Sood A, Vetterlein MW, Karabon P, Jeong W, Menon M, Trinh QD, Abdollah F. Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses. Urol Oncol. 2017 07; 35(7):460.e9-460.e20.
Score: 0.120
-
Sammon JD, Dalela D, Abdollah F, Choueiri TK, Han PK, Hansen M, Nguyen PL, Sood A, Menon M, Trinh QD. Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. J Urol. 2016 04; 195(4 Pt 1):913-8.
Score: 0.110
-
Pucheril D, Sammon JD, Sood A, Abdollah F, Choueiri TK, Meyer C, Hanske J, Kim SP, Nguyen PL, Kibel AS, Weissman JS, Menon M, Trinh QD. Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urol Oncol. 2015 Dec; 33(12):503.e7-15.
Score: 0.108
-
Pucheril D, Dalela D, Sammon J, Sood A, Sun M, Trinh QD, Menon M, Abdollah F. The influence of physician recommendation on prostate-specific antigen screening. Urol Oncol. 2015 Oct; 33(10):424.e1-7.
Score: 0.107
-
Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015 Sep; 68(3):497-505.
Score: 0.107
-
Abdollah F, Klett DE, Sood A, Sammon JD, Pucheril D, Dalela D, Diaz M, Peabody JO, Trinh QD, Menon M. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU Int. 2015 Nov; 116(5):703-12.
Score: 0.106
-
Bertini A, Tylecki A, Stephens A, Finocchiaro A, Vigan? S, Cusmano N, Dinesh A, Guivatchian E, Lughezzani G, Buffi N, Di Trapani E, Ficarra V, Briganti A, Salonia A, Montorsi F, Sood A, Rogers C, Abdollah F. Socioeconomic Disparities in Prostate Cancer Presentation: The Impact of ADI on Prostate Cancer Stage at Diagnosis. Clin Genitourin Cancer. 2025 Dec; 23(6):102418.
Score: 0.054
-
Bertini A, Stephens A, Finocchiaro A, Silvia V, Arjun D, Elnaz G, Nicholas C, Lughezzani G, Buffi N, Di Trapani E, Ficarra V, Briganti A, Salonia A, Montorsi F, Sood A, Rogers C, Abdollah F. Association of Area of Deprivation Index With Active Surveillance (AS) Utilization and Adherence to as Guidelines: Results From a Contemporary North American Cohort. Prostate. 2025 Aug; 85(11):1024-1035.
Score: 0.053
-
Finati M, Morrison C, Stephens A, Chiarelli G, Cirulli GO, Tinsley S, Davis M, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Bettocchi C, Rogers C, Carrieri G, Abdollah F. Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts. Prostate. 2025 Jan; 85(1):82-89.
Score: 0.051
-
Modonutti D, Majdalany SE, Butaney M, Davis MJ, Corsi N, Sood A, Trinh QD, Cole AP, Rogers CG, Novara G, Abdollah F. Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel. Prostate. 2023 09; 83(13):1238-1246.
Score: 0.046
-
Andrews JR, Sood A, Chapin BF. Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer. J Urol. 2023 08; 210(2):242-243.
Score: 0.046
-
Andrews JR, Ahmed ME, Sharma V, Britton C, Stish B, Phillips R, Kendi AT, Joshi VB, Sood A, Tollefson MK, Boorjian SA, Karnes RJ, Kwon ED. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022 12; 208(6):1240-1249.
Score: 0.044
-
Rakic N, Sood A, Dalela D, Arora S, Malovana U, Keeley J, Rogers C, Peabody J, Menon M, Abdollah F. A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients. Clin Genitourin Cancer. 2020 12; 18(6):489-499.e6.
Score: 0.037
-
Menon M, Dalela D, Jamil M, Diaz M, Tallman C, Abdollah F, Sood A, Lehtola L, Miller D, Jeong W. Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy: An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. J Urol. 2018 05; 199(5):1210-1217.
Score: 0.032
-
Dalela D, Karabon P, Sammon J, Sood A, L?ppenberg B, Trinh QD, Menon M, Abdollah F. Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer. Eur Urol. 2017 04; 71(4):511-514.
Score: 0.029
-
Moschini M, Fossati N, Sood A, Lee JK, Sammon J, Sun M, Pucheril D, Dalela D, Montorsi F, Karnes RJ, Briganti A, Trinh QD, Menon M, Abdollah F. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. Eur Urol Focus. 2018 01; 4(1):68-74.
Score: 0.029
-
Abdollah F, Moschini M, Sood A, Sammon J, Dalela D, Hsu L, Beyer B, Haese A, Graefen M, Gandaglia G, Montorsi F, Briganti A, Menon M. When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database. J Endourol. 2016 Feb; 30(2):201-7.
Score: 0.027
-
Abdollah F, Sammon JD, Majumder K, Reznor G, Gandaglia G, Sood A, Hevelone N, Kibel AS, Nguyen PL, Choueiri TK, Selvaggi KJ, Menon M, Trinh QD. Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2015 Sep; 13(9):1131-8.
Score: 0.027